In the LAURA trial, 56% of patients remained MRD-positive after definitive chemoradiation. This indicates that local therapy is often insufficient to eradicate the disease, suggesting early micrometastasis is common and providing a strong rationale for consolidation therapy.
Data from the WUCONG-1B trial shows the TKI sunvosertinib's response rate is nearly halved in patients with prior exposure to the antibody amivantamab. This suggests a potential lack of efficacy after amivantamab and has major implications for treatment sequencing in this disease.
The LAURA trial shows a favorable overall survival trend for osimertinib consolidation even though 80% of placebo patients received osimertinib upon progression. This high crossover rate makes the persistent trend highly significant, suggesting a strong benefit to earlier TKI administration.
While research pursues mechanism-based strategies (e.g., 4th-gen TKIs) for acquired resistance, recent practical breakthroughs are mechanism-agnostic, like ADCs or chemotherapy combinations. This highlights a pragmatic, broad-spectrum approach to treating progression after frontline osimertinib.
The ADAURA trial's MRD analysis reveals that a negative ctDNA test after surgery is not a reliable indicator of being cured. Patients still require adjuvant therapy, as recurrence remains a significant risk, especially within 12 months after stopping treatment.
Dr. Ramalingam describes a nuanced clinical approach based on early NEO ADORA data: using neoadjuvant chemo-osimertinib for N2 positive (Stage 3A) patients, but favoring upfront surgery followed by adjuvant therapy for Stage 2. This shows how specialists apply preliminary findings before they become universal standards.